Global Capivasertib Market Strategic Research Report

Scope of the Report

The global Capivasertib market size is predicted to grow from US$ 712 million in 2025 to US$ 2,751 million in 2032; it is expected to grow at a CAGR of 15.2% from 2026 to 2032.

Capivasertib is an oral, highly selective ATP-competitive AKT kinase inhibitor that potently inhibits the activities of AKT1/2/3 isoforms, blocks the abnormal activation of the PI3K/AKT signaling pathway, and thereby inhibits the proliferation, survival, invasion and metastasis of tumor cells. The drug is mainly developed for patients with solid tumors harboring PIK3CA/AKT1/PTEN mutations. Clinically, it is mostly used in combination with endocrine therapy for HR-positive, HER2-negative advanced breast cancer, and is also under investigation in various tumor types such as prostate cancer and colorectal cancer, providing precise targeted therapeutic options for advanced cancer patients with abnormalities in specific signaling pathways.In 2025, global Capivasertib production reached approximately 1.8 million bottles.

Capivasertib has established a core position in the treatment of HR-positive, HER2-negative advanced breast cancer by virtue of its first-mover advantage as the world’s first-in-class AKT inhibitor and a clear biomarker selection strategy. By continuously expanding its pipeline to cover multiple tumor types such as prostate cancer, it has built a broad market space. Its mechanism of action, which precisely targets the PI3K/AKT pathway, aligns perfectly with the mainstream trend of precision and individualized cancer therapy, effectively filling the clinical gap for patients with endocrine resistance. The current market landscape is oligopolistic. As the only approved AKT inhibitor on the market, Capivasertib faces limited direct competition, with only a few similar drugs in late clinical stages. With gradual market access in major global regions, the popularization of companion diagnostics, and the continuous expansion of indications, the drug is rapidly penetrating from second-line breast cancer treatment to more tumor types. It boasts significant long-term commercialization potential and is expected to become a key product driving the growth of AstraZeneca’s oncology business.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Capivasertib market?

What factors are driving Capivasertib market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Capivasertib market opportunities vary by end market size?

How does Capivasertib break out by Type, by Application?

This report presents a comprehensive overview of the global Capivasertib market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 160 mg
• 200 mg

Segment by Combination Therapy

• Capivasertib In Combination With Fulvestrant
• Capivasertib In Combination With Letrozole

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• HR-Positive, HER2-Negative Advanced Breast Cancer
• Metastatic Prostate Cancer
• Advanced Colorectal Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Capivasertib market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in HR-Positive, HER2-Negative Advanced Breast Cancer, Metastatic Prostate Cancer, Advanced Colorectal Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact